IL158384A0 - Treatment or prophylaxis of insulin producing cell graft rejection - Google Patents
Treatment or prophylaxis of insulin producing cell graft rejectionInfo
- Publication number
- IL158384A0 IL158384A0 IL15838402A IL15838402A IL158384A0 IL 158384 A0 IL158384 A0 IL 158384A0 IL 15838402 A IL15838402 A IL 15838402A IL 15838402 A IL15838402 A IL 15838402A IL 158384 A0 IL158384 A0 IL 158384A0
- Authority
- IL
- Israel
- Prior art keywords
- graft rejection
- producing cell
- prophylaxis
- cell graft
- treatment
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004877 Insulin Human genes 0.000 title abstract 2
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 206010052779 Transplant rejections Diseases 0.000 title abstract 2
- 229940125396 insulin Drugs 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 229940124073 Complement inhibitor Drugs 0.000 abstract 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000004074 complement inhibitor Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29706901P | 2001-06-08 | 2001-06-08 | |
| PCT/EP2002/006278 WO2002100148A2 (en) | 2001-06-08 | 2002-06-07 | Treatment or prophylaxis of insulin-producing cell graft rejection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158384A0 true IL158384A0 (en) | 2004-05-12 |
Family
ID=23144725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15838402A IL158384A0 (en) | 2001-06-08 | 2002-06-07 | Treatment or prophylaxis of insulin producing cell graft rejection |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20030003099A1 (enExample) |
| EP (1) | EP1429845B1 (enExample) |
| JP (1) | JP4476623B2 (enExample) |
| CN (1) | CN1524002A (enExample) |
| AT (1) | ATE424893T1 (enExample) |
| AU (1) | AU2002320828B2 (enExample) |
| BR (1) | BR0209319A (enExample) |
| CA (1) | CA2445605A1 (enExample) |
| DE (1) | DE60231522D1 (enExample) |
| ES (1) | ES2322442T3 (enExample) |
| IL (1) | IL158384A0 (enExample) |
| NO (1) | NO20035434D0 (enExample) |
| NZ (1) | NZ529044A (enExample) |
| PL (1) | PL364359A1 (enExample) |
| PT (1) | PT1429845E (enExample) |
| RU (1) | RU2003136730A (enExample) |
| WO (1) | WO2002100148A2 (enExample) |
| ZA (1) | ZA200307893B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4318921B2 (ja) * | 2001-02-22 | 2009-08-26 | ノバルティス アクチエンゲゼルシャフト | 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用 |
| EP2338511A3 (en) * | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| CN101905023B (zh) * | 2004-07-16 | 2012-07-11 | 杏林制药株式会社 | 有效的医药使用方法及与副作用发生的防御相关的方法 |
| EP2384749A1 (en) * | 2004-11-29 | 2011-11-09 | Novartis AG | Dosage regimen of an S1P receptor agonist |
| AU2006212866A1 (en) * | 2005-02-08 | 2006-08-17 | Novartis Ag | Antilymphocyte antibody induction by combination of an S1P receptor agonist/modulator and of immunosuppressive drugs |
| WO2006124375A2 (en) * | 2005-05-11 | 2006-11-23 | Loma Linda University | Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders |
| US20090191218A1 (en) | 2005-05-11 | 2009-07-30 | Fengchun Li | DNA Vaccines And Methods For The Prevention Of Transplantation Rejection |
| RU2433117C2 (ru) | 2005-12-15 | 2011-11-10 | Мицубиси Танабе Фарма Корпорейшн | Аминное соединение и его применение в медицинских целях |
| BRPI0708424A2 (pt) * | 2006-03-02 | 2011-05-31 | Alexion Pharma Inc | prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento |
| WO2008039980A2 (en) * | 2006-09-28 | 2008-04-03 | Loma Linda University | Apoptotic cell-mediated transfection of mammalian cells with interfering rna |
| JP5452237B2 (ja) | 2008-02-07 | 2014-03-26 | 杏林製薬株式会社 | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
| AU2009223148B2 (en) * | 2008-03-12 | 2013-03-14 | Loma Linda University | DNA vaccines and methods for the prevention of transplantation rejection |
| CA2716448A1 (en) | 2008-03-17 | 2009-09-24 | Patrick Brossard | Dosing regimen for a selective s1p1 receptor agonist |
| JP2012508215A (ja) * | 2008-11-11 | 2012-04-05 | ノバルティス アーゲー | 有機化合物 |
| CN104788325A (zh) * | 2008-11-11 | 2015-07-22 | 诺华股份有限公司 | 芬戈莫德的结晶形式 |
| CA2766944C (en) * | 2009-06-30 | 2019-10-29 | Lifescan, Inc. | Analyte testing methods and device for calculating basal insulin therapy |
| CA2766870A1 (en) * | 2009-06-30 | 2011-01-06 | Lifescan Scotland Limited | Systems for diabetes management and methods |
| CN103976741B (zh) * | 2009-09-29 | 2017-02-22 | 生命扫描苏格兰有限公司 | 用于糖尿病管理的被分析物测试方法和装置 |
| CN102770868B (zh) * | 2010-02-25 | 2017-02-22 | 生命扫描苏格兰有限公司 | 具有高低血糖趋势通知的分析物测试方法和系统 |
| WO2013044177A2 (en) | 2011-09-23 | 2013-03-28 | Loma Linda University | Bacterial strains expressing methylase genes and uses thereof |
| US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
| CN114306643A (zh) * | 2021-11-30 | 2022-04-12 | 中国科学院昆明动物研究所 | 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0155015B1 (ko) * | 1992-10-21 | 1998-12-01 | 고우야 마사시 | 2-아미노-1,3-프로판디올 화합물 및 면역 억제제 |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| CA2184356A1 (en) * | 1994-03-03 | 1995-09-08 | Russell P. Rother | Terminal complement inhibitor fusion genes and proteins |
| GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP4318921B2 (ja) * | 2001-02-22 | 2009-08-26 | ノバルティス アクチエンゲゼルシャフト | 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用 |
-
2002
- 2002-06-07 ES ES02754637T patent/ES2322442T3/es not_active Expired - Lifetime
- 2002-06-07 RU RU2003136730/15A patent/RU2003136730A/ru not_active Application Discontinuation
- 2002-06-07 IL IL15838402A patent/IL158384A0/xx unknown
- 2002-06-07 AU AU2002320828A patent/AU2002320828B2/en not_active Ceased
- 2002-06-07 JP JP2003502981A patent/JP4476623B2/ja not_active Expired - Fee Related
- 2002-06-07 PL PL02364359A patent/PL364359A1/xx not_active Application Discontinuation
- 2002-06-07 DE DE60231522T patent/DE60231522D1/de not_active Expired - Lifetime
- 2002-06-07 NZ NZ529044A patent/NZ529044A/en unknown
- 2002-06-07 EP EP02754637A patent/EP1429845B1/en not_active Expired - Lifetime
- 2002-06-07 WO PCT/EP2002/006278 patent/WO2002100148A2/en not_active Ceased
- 2002-06-07 BR BR0209319-7A patent/BR0209319A/pt not_active IP Right Cessation
- 2002-06-07 CN CNA028098498A patent/CN1524002A/zh active Pending
- 2002-06-07 PT PT02754637T patent/PT1429845E/pt unknown
- 2002-06-07 CA CA002445605A patent/CA2445605A1/en not_active Abandoned
- 2002-06-07 AT AT02754637T patent/ATE424893T1/de active
- 2002-06-07 US US10/164,755 patent/US20030003099A1/en not_active Abandoned
-
2003
- 2003-10-09 ZA ZA200307893A patent/ZA200307893B/en unknown
- 2003-12-05 NO NO20035434A patent/NO20035434D0/no not_active Application Discontinuation
-
2006
- 2006-03-09 US US11/372,383 patent/US20060153842A1/en not_active Abandoned
-
2008
- 2008-04-22 US US12/107,726 patent/US20080199465A1/en not_active Abandoned
-
2011
- 2011-06-06 US US13/154,106 patent/US20110236382A1/en not_active Abandoned
-
2013
- 2013-12-05 US US14/098,179 patent/US20140093502A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4476623B2 (ja) | 2010-06-09 |
| JP2004534788A (ja) | 2004-11-18 |
| US20110236382A1 (en) | 2011-09-29 |
| EP1429845A2 (en) | 2004-06-23 |
| CA2445605A1 (en) | 2002-12-19 |
| ATE424893T1 (de) | 2009-03-15 |
| DE60231522D1 (de) | 2009-04-23 |
| NO20035434D0 (no) | 2003-12-05 |
| PT1429845E (pt) | 2009-06-15 |
| US20030003099A1 (en) | 2003-01-02 |
| CN1524002A (zh) | 2004-08-25 |
| US20080199465A1 (en) | 2008-08-21 |
| EP1429845B1 (en) | 2009-03-11 |
| US20060153842A1 (en) | 2006-07-13 |
| NZ529044A (en) | 2008-03-28 |
| RU2003136730A (ru) | 2005-05-20 |
| ZA200307893B (en) | 2004-09-06 |
| BR0209319A (pt) | 2004-07-20 |
| AU2002320828B2 (en) | 2006-02-02 |
| US20140093502A1 (en) | 2014-04-03 |
| WO2002100148A3 (en) | 2004-04-22 |
| ES2322442T3 (es) | 2009-06-22 |
| WO2002100148A2 (en) | 2002-12-19 |
| PL364359A1 (en) | 2004-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL364359A1 (en) | Treatment or prophylaxis of insulin-producing cell graft rejection | |
| DE69713151D1 (de) | Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung | |
| NO954996L (no) | Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS | |
| UA49869C2 (uk) | Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора | |
| IL122546A0 (en) | Use of a combination of ritonavir and a drug metabolized by cytochrome p450 monooxygenase in the preparation of medicaments and pharmaceutical compositions containing the combination | |
| UA41995C2 (uk) | Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти ) | |
| EA200200392A1 (ru) | Способ получения экстракта из растения рода trichocaulon или рода hoodia, экстракт, порошковый материал и композиция на его основе и их применение для производства медикамента для лечения, профилактики или преодоления ожирения и/или подавления аппетита | |
| NZ514574A (en) | Novel method of treatment | |
| GEP20002013B (en) | Therapeutical Means | |
| NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
| DK0828500T3 (da) | Anvendelse af flavanyllignaner til fremstilling af lægemidler med proliferativ aktivitet i uturus, ovarie og bryst | |
| SG47977A1 (en) | C-22 stabilized rapamycin derivatives | |
| HU9302496D0 (en) | Method for producing anti-viral nucleoside combinations and one for preparing medical preparatives containing said compounds | |
| AU7239996A (en) | Inhibition of tumor necrosis factor alpha | |
| AU2855399A (en) | Vascularization inhibitors | |
| IS5082A (is) | Pýrróló[3,4-D]pýrimídínon-afleiður og notkun þeirra sem lyfja | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| IL127542A0 (en) | Administration regimen of H+ K+ -ATPase inhibitors | |
| WO2004031129A3 (en) | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | |
| EE9900588A (et) | CD154 blokaadravi pankreasesaarte koe transplantatsiooni korral | |
| CY2462B1 (en) | Cyclohexyl dihydrobenzofuranes. | |
| WO2001078653A3 (en) | Graft rejection inhibition with ccr2 inhibitors | |
| NZ330944A (en) | Peptide derivatives | |
| EP0663835A1 (en) | USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS. | |
| ZA991029B (en) | Composition and methods for treatment of hiv infections. |